La Jolla Pharmaceutical Company (LJPC): Why analyst showing interest

0
33

La Jolla Pharmaceutical Company (NASDAQ:LJPC) changes shares on Tuesday trading session, with a change of 4.93% or $0.2 shares. The trading starts at $4.02 and closed at $4.06 throughout the day. The trading session low price was $4.02 and day high was $4.34 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 0.39 million while its average volume is 683.52K. In other hand, the LJPC market cap reached to $122.13M.

On June 24, 2020, BRIEF-La Jolla Pharmaceutical Company To Acquire Tetraphase Pharmaceuticals. According to the news reported on Reuters, * LA JOLLA PHARMACEUTICAL COMPANY TO ACQUIRE TETRAPHASE PHARMACEUTICALS, INC.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 9.51% and down -4.05% for month. Its quarterly performance was -43.80% below, while its half year performance is down -49.23%. LJPC yearly performance stood at negative -49.76% and rise 8.40% for year-to-date. Current recommendation for La Jolla Pharmaceutical Company is 2.30.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. LJPC EPS (TTM) for 12-month is -3.44. EPS for this year is 45.20%, while for the next year its value is -1.03. Its EPS Q/Q reached 73.10%. It has an EPS of -16.60% down for past five years and for the next five years will be up 13.20%.

Let’s take a look on the analyst recommendations on LJPC for the current month and previous month. For the current month, 2 of 3 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 1 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $4.00 – $20.00. Average target price for LJPC was reached at $10.67.

The insider ownership moved to 0.40% and institutional holding shifted to 84.40%.

The company posted an EPS (TTM) of -3.44. According to the most recent quarter report on (Jun 2020), 2 analysts estimated an average EPS of -0.41, while -1.12 EPS posted a year ago period. Analyst Estimated EPS for LJPC published in the report was -$0.44 – -$0.38 during the same period. Comparing with last year, the average estimated EPS was -1.12 which is lower than -0.32 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for LJPC fall -25.86% for period of 200 days. SMA for 50 days was -10.98% which is showing red signal, while SMA-20 was -0.03%. The moving average value for La Jolla Pharmaceutical Company (LJPC) is 3.5M and 10.94% for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in LJPC stock. On Jun 04, TANG KEVIN C, Director, bought 215,812 trading shares at the cost of $4.94, which valued at 1.07 million. On Jun 03, TANG KEVIN C, Director, bought 145,764 shares at the cost of $4.90, with total shares of 8,479,662. On Jun 02, TANG KEVIN C, Director, bought 253,553 shares at the cost of 4.88. After this transaction, TANG KEVIN C total shares reached to 8,333,898 which valued at 1.24 million.